Chaitong Churuangsuk MD

Phd candidate in Human Nutrition @ U of Glasgow | Medical Instructor, Clin Nutr & Obes Med Unit, Faculty of Medicine, Prince of Songkla Uni, | #madeinThailand

[Chaitong Churuangsuk MD @ChaitongMD]

Finally I DID IT 🎉🥳 delighted I passed my PhD viva today! Thank you very kind examiners for a lovely and supportive examination. Super thanks to my supervisors @EmilieCombet @MEJLean who shaped me and helped me become a researcher 🥳❤️ #phdchat #UofGlasgow @Gla_nutrition

[Eric Topol @EricTopol]

The benefit of Ozempic (semaglutide) for protection from major adverse cardiovascular events (MACE) is independent of weight loss magnitude and baseline adiposity, likely related to the GLP-1 anti-inflammatory effect
https://t.co/y44fRowTGi

[Scott Isaacs @scottisaacsmd]

Organ-specific imaging biomarkers in obesity care. MRI, CT, PET, & ultrasonography now quantify adiposity, fibrosis, heart & brain changes, and pancreatic dysfunction. Automation & AI enable whole-body MRI segmentation for subcutaneous/visceral fat and muscle, guiding risk stratification and therapy.
https://t.co/9qO6XZJkeX

[EASO @EASOobesity]

📢The EASO Algorithm for the pharmacological treatment of obesity and its complications has been published in @NatureMedicine

Developed using rigorous analysis, it provides clinically relevant guidance for personalised medication management. https://t.co/SLb8bIRyZW
@busetto_luca

[Cell Metabolism @Cell_Metabolism]

Shivering, but not adipose tissue thermogenesis, increases as a function of mean skin temperature in cold-exposed men and women https://t.co/UHeDLmgctK

[EASO @EASOobesity]

Obesity is a multifactorial, chronic, relapsing, non-communicable disease with an abnormal and/or excessive accumulation of body fat that presents a risk to health.

➡️ A framework for the diagnosis, staging and management of obesity in adults.

https://t.co/aSeURbId51

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical link connecting digestion, metabolism, & cardiovascular function, supporting physiological adaptations to nutrient intake https://t.co/6Vaei6pmAD
#GLP-1 #GIP

[EASO @EASOobesity]

Most people think in terms of short-term weight loss rather than long-term obesity treatment.

This is not at all how we think about other chronic conditions like diabetes or high blood pressure. 

Great blog post, Ted! Obesity Treatment Is a Marathon, Not a Sprint @Conscienhealth

https://t.co/Bkcyoil1jV

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

Recovery of β-cell function is the dominant determinant of the remission of prediabetes, akin to its role in remission of diabetes but at an earlier point in the natural history of dysglycaemia https://t.co/3Opnc3CM3L
#prediabetes #remission

[ESPEN @ESPENorg]

IMPLEMENTATION OF HOME PARENTERAL NUTRITION (#HPN)
Operational recommendations according to the ESPEN guidelines
The implementation of HPN follows a structured four-step process to ensure clinical appropriateness, logistical readiness, and patient safety.
How to achieve the best results for your patients with #HPN
https://t.co/e7UNgvoUau
#Nutritionmatters #Nutritionisahumanright

[Michael Albert, MD @MichaelAlbertMD]

🚨First RCT Finds Semaglutide May Slow Biological Aging
- - -
A 32-week placebo-controlled RCT just delivered the first human evidence that semaglutide may do more than aid weight loss—it may turn back your biological clock.

🧬The Science
Epigenetic “aging clocks” track how fast your cells age, based on DNA methylation—not birthdays.

📊 Key Findings
Primary biomarkers:
🔹PCGrimAge ↓ 3.1 years (p=0.007)
🔹PhenoAge ↓ 4.9 years (p=0.004)
🔹DunedinPACE ~9% slower aging pace (p=0.01)
🔹OMICmAge ↓ 2.2 years (p=0.009)

Organ-specific:
🧠 Brain: –5.0 years
🫀 Heart: –4.3 years
🔥 Inflammation: –5.0 years
⚡ Metabolic: –4.7 years
🩸 Blood: –4.4 years

🎯 Why It’s Big
✅ First-ever RCT of a GLP-1 drug on aging biomarkers
✅ Consistent benefits across nearly all measures
✅ Multi-organ effects, not just metabolic

⚠️ Caveats
Preprint (not yet peer-reviewed)
Small study (n=84)
Short duration (32 weeks)
HIV+ lipohypertrophy population
Biomarkers—not clinical endpoints (yet)

🔮 What’s Next
Larger, longer trials in broader populations to see if these biomarker shifts translate to real-world healthspan gains.

The first FDA-approved anti-aging drug candidate? This study makes a strong case.

Corley et al., July 2025, medRxiv
🔗 https://t.co/uzdPphxJ7q

[EASO @EASOobesity]

New article in Springer Nature: Body Mass Index Progression, Development of Complications and Healthcare Costs Over 8 Years in UK Individuals Living With Overweight/Obesity

Read more: https://t.co/7mV2jOzJ75

@busetto_luca

[Michael Albert, MD @MichaelAlbertMD]

📉 What REALLY happens when you stop anti‑obesity meds?
- - -
A new meta‑analysis [Wu et al., BMC Medicine, 2025] just mapped the weight regain trajectory after stopping GLP‑1s and other AOMs—and it’s eye‑opening.

Key findings:
⏳ First month off: Weight loss continues briefly (~4 weeks).

📈 By week 8: Regain starts.

🔄 Weeks 8–20: Rapid regain — often 2–3 kg above discontinuation weight.

🪂 After ~6 months: Regain levels off, but most patients keep some net loss vs. baseline.

💉 GLP‑1s hit harder: GLP‑1–based drugs showed the most pronounced regain.

🏋️‍♀️ Lifestyle changes help… but not enough: Even with ongoing diet/exercise programs, regain still occurred.

Why?
🔹Appetite & hunger hormones rebound.
🔹Stomach emptying speeds back up.
🔹Metabolic rate adjusts downward after weight loss.

The takeaway:
Stopping AOMs ≠ “you’re cured.” Obesity is a chronic condition — and without ongoing treatment (whether medication, surgery, or intensive behavioral support), biology will try to pull weight back up.
🔗https://t.co/fP6jHaY91i

[Javier Gonzalez @Gonzalez_JT]

The mixed-meal tolerance test in appetite research
🧵

Topics covered:
-Familiarisation/Standardisation 🟰
-Meal stimulus 🥣
-Appetite scales 😋
-Blood sampling 💉
-Blood analyses 🩸
-Data handling 📊
https://t.co/1HE2T4jsWq
@CNEM_Bath

[Eric Topol @EricTopol]

The anti-inflammatory power of semaglutide (Ozempic) seen by its normalization to healthy of a 72 protein signature tied to MASH liver disease
https://t.co/qVZFeqLiUU
@NatureMedicine

[Andy Galpin, PhD @DrAndyGalpin]

It's not just genetics.

Or just lifestyle.

Disease & peak health are both just expressions of an incredibly complicated ongoing physiological mosaic.

One must account for genomics, epigenomics, transcriptomics, proteomics, phophoproteomics, and much more.

Focusing on muscle hypertrophy, this recent (open access) paper by my long-time friend @KevinMurachPhD does a great job of breakdown what this all is and how it works.

Safe to say, much is left to learn.

[Daniel J Drucker @DanielJDrucker]

Studies from mice and humans reveal that semaglutide may revert the circulating proteome associated with #MASH to the proteomic pattern observed in healthy individuals reducing #inflammation #fibrosis
https://t.co/EqF8KSKzbO

[Eric Topol @EricTopol]

The mechanisms by which ultra-processed foods (UPF) drive obesity, an outstanding review article
"the evidence is sufficiently strong to justify immediate public health efforts to reduce UPF consumption."
https://t.co/j03odD6ym0

[Michael Weintraub, MD @MWeintraubMD]

Excellent presentation by Dr. Angela Rao on peri-operative GLP1 use before and after bariatric surgery at #ENDO2025!
@dimpi_desai

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

Hypothalamic obesity: from basic mechanisms to clinical perspectives https://t.co/3Be0ZzCY6R
#ENDO2025

[Prof Kamlesh Khunti @kamleshkhunti]

Aetiology of type 2 diabetes: an experimental medicine odyssey

Review by Roy Taylor

https://t.co/DiLvSAY7Ip